Raymond James & Associates’s Exelixis EXEL Stock Holding History

Raymond James & Associates’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,000	Closed	-$30K	–	4006
2022 Q2	$30K	Sell	29,000 -200	-0.7%	-$4.12K	﹤0.01%	3841
2022 Q1	$88K	Buy	+29,200	New	+$570K	﹤0.01%	3848
2021 Q3	–	Sell	-29,900	Closed	-$79K	–	4167
2021 Q2	$79K	Buy	+29,900	New	+$697K	﹤0.01%	3871
2020 Q3	–	Sell	-33,600	Closed	-$67K	–	3611
2020 Q2	$67K	Sell	33,600 -1,000	-3%	-$23.2K	﹤0.01%	3346
2020 Q1	$59K	Buy	+34,600	New	+$633K	﹤0.01%	3296
2019 Q4	–	Sell	-26,900	Closed	-$16K	–	3692
2019 Q3	$16K	Sell	26,900 -60,700	-69%	-$1.23M	﹤0.01%	3547
2019 Q2	$87K	Sell	87,600 -29,100	-25%	-$610K	﹤0.01%	3432
2019 Q1	$245K	Buy	116,700 +87,900	+305%	+$2M	﹤0.01%	3094
2018 Q4	$101K	Sell	28,800 -700	-2%	-$12.5K	﹤0.01%	3302
2018 Q3	$116K	Buy	+29,500	New	+$575K	﹤0.01%	3415

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James & Associates's EXEL Position: Q3 2024 in Review

Raymond James & Associates increased its Exelixis (EXEL) stake by 118% in Q3 2024, buying an estimated $3.23M and bringing the position to 239,661 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Raymond James & Associates first reported a position in EXEL in Q3 2017 and has held it in 29 quarters since. The position peaked at $8.25M in Q1 2019. 453 funds tracked by Wall St. Rank hold EXEL as of Q3 2024.

Raymond James & Associates held 239,661 shares of Exelixis worth $6.22M as of Q3 2024.
Raymond James & Associates bought 129,805 Exelixis shares in Q3 2024, an estimated $3.23M.
Exelixis made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1506 holding.
Raymond James & Associates first reported a position in Exelixis in Q3 2017 and has held it in 29 quarters since.
Raymond James & Associates's Exelixis position peaked at $8.25M in Q1 2019.
453 funds tracked by Wall St. Rank held Exelixis as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.